Stay updated on Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Sign up to get notified when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.

Latest updates to the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedGlossary toggle controls (Show glossary / Hide glossary) were added, and minor wording/capitalization changes were made to update metadata (e.g., Last Update Submitted that Met QC Criteria vs Last Update Submitted that met QC Criteria, No FEAR Act Data vs No FEAR Act data), plus a revision note 'Revision: v3.4.0'. These changes affect presentation and metadata only and do not alter core study content or functionality.SummaryDifference0.2%

- Check26 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page header.SummaryDifference0.0%

- Check54 days agoChange DetectedAdded a new 'Locations' section with subsections for Arizona, Florida, and Minnesota, consolidating site information under 'Locations'. Removed the separate 'Arizona Locations', 'Florida Locations', and 'Minnesota Locations' entries and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check76 days agoChange DetectedPublications note is now described as automatically filled from PubMed, and the Revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check83 days agoChange DetectedRemoved a government funding status notice banner from the page; this is a minor administrative change that does not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Ixazomib Citrate for Relapsed Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ixazomib Citrate for Relapsed Myeloma Clinical Trial page.